Panagiotis Balermpas

List of Publications by Year
in descending order

121 papers	2,831 citations	218381 26 h-index	205818 48 g-index
132 all docs	132 docs citations	132 times ranked	4235 citing authors

#	Article	IF	Citations
1	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer, 2016, 138, 171-181.	2.3	184
2	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Scientific Reports, 2017, 7, 13206.	1.6	163
3	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
4	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
5	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
6	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
7	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
8	Human papilloma virus load and PD-1/PD-L1, CD8⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. OncoImmunology, 2017, 6, e1288331.	2.1	79
9	Human papillomavirus DNA load and p16^{INK4a}expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. International Journal of Cancer, 2015, 136, 278-288.	2.3	75
10	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. OncoImmunology, 2014, 3, e27403.	2.1	61
11	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentreÂretrospective study of the German Cancer Consortium Radiation Oncology Group. European Journal of Cancer, 2019, 116, 67-76.	1.3	58
12	S2k Guidelines for Cutaneous Basal Cell Carcinoma â€“ Part 2: Treatment, Prevention and Followâ€up. JDDG - Journal of the German Society of Dermatology, 2019, 17, 214-230.	0.4	57
13	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
14	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
15	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. PLoS ONE, 2018, 13, e0198692.	1.1	47
16	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
17	S2k Guidelines for Cutaneous Basal Cell Carcinoma â€“ Part 1: Epidemiology, Genetics and Diagnosis. JDDG - Journal of the German Society of Dermatology, 2019, 17, 94-103.	0.4	44
18	Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck. Strahlentherapie Und Onkologie, 2009, 185, 775-781.	1.0	43

#	Article	IF	Citations
19	Anal squamous cell carcinoma â€“ State of the art management and future perspectives. Cancer Treatment Reviews, 2018, 65, 11-21.	3.4	37
20	MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges. Frontiers in Oncology, 2021, 11, 616156.	1.3	37
21	Treatment plan quality during online adaptive re-planning. Radiation Oncology, 2020, 15, 203.	1.2	36
22	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	2.9	34
23	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 15625.	1.6	34
24	Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site â€“ current status and challenges. Radiation Oncology, 2017, 12, 82.	1.2	33
25	Reirradiation With Cetuximab in Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck: Feasibility and First Efficacy Results. International Journal of Radiation Oncology Biology Physics, 2012, 83, e377-e383.	0.4	31
26	Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiotherapy and Oncology, 2020, 144, 209-217.	0.3	30
27	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. Frontiers in Immunology, 2017, 8, 1225.	2.2	29
28	Radiomic biomarkers for head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2020, 196, 868-878.	1.0	28
29	Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	27
30	Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research, 2019, 29, 187-195.	0.6	27
31	Breathing-motion-compensated robotic guided stereotactic body radiation therapy. Strahlentherapie Und Onkologie, 2018, 194, 143-155.	1.0	26
32	Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. Frontiers in Oncology, 2018, 8, 171.	1.3	26
33	Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlentherapie Und Onkologie, 2015, 191, 656-664.	1.0	25
34	Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. International Journal of Molecular Sciences, 2018, 19, 2485.	1.8	25
35	Dimethylfumarate Inhibits Colorectal Carcinoma Cell Proliferation: Evidence for Cell Cycle Arrest, Apoptosis and Autophagy. Cells, 2019, 8, 1329.	1.8	25
36	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24

#	Article	IF	Citations
37	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. OncoImmunology, 2019, 8, 1614858.	2.1	24
38	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. Cancers, 2019, 11, 472.	1.7	24
39	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.3	24
40	Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. International Journal of Cancer, 2021, 149, 358-370.	2.3	24
41	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 221-230.	3.3	23
42	S2kâ€Leitlinie Basalzellkarzinom der Haut â€“ Teil 1: Epidemiologie, Genetik und Diagnostik. JDDG - Journal of the German Society of Dermatology, 2019, 17, 94-104.	0.4	23
43	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
44	Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck. Strahlentherapie Und Onkologie, 2016, 192, 25-31.	1.0	22
45	S2kâ€Leitlinie Basalzellkarzinom der Haut â€“ Teil 2: Therapie, PrÃvention und Nachsorge. JDDG - Journal of the German Society of Dermatology, 2019, 17, 214-231.	0.4	19
46	C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. Frontiers in Oncology, 2019, 9, 1200.	1.3	19
47	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. Cancers, 2020, 12, 3047.	1.7	19
48	Combined protonâ€“photon treatments â€“ A new approach to proton therapy without a gantry. Radiotherapy and Oncology, 2020, 145, 81-87.	0.3	19
49	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. Frontiers in Oncology, 2019, 9, 20.	1.3	18
50	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
51	Head and neck radiotherapy on the MR linac: aÂmulticenter planning challenge amongst MRIdian platform users. Strahlentherapie Und Onkologie, 2021, 197, 1093-1103.	1.0	17
52	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16
53	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncology, 2020, 111, 104931.	0.8	16
54	RADIANCE â€“ Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	0.9	16

#	Article	IF	Citations
55	Dental extraction, intensity-modulated radiotherapy of head and neck cancer, and osteoradionecrosis. Strahlentherapie Und Onkologie, 2022, 198, 219-228.	1.0	16
56	Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiation Oncology, 2017, 12, 138.	1.2	14
57	Patterns of care analysis for head & neck cancer of unknown primary site: aÂsurvey inside the German society of radiation oncology (DEGRO). Strahlentherapie Und Onkologie, 2018, 194, 750-758.	1.0	13
58	MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. Cancers, 2021, 13, 5404.	1.7	13
59	Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. Radiation Oncology, 2021, 16, 217.	1.2	13
60	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 126-137.	3.3	12
61	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget, 2016, 7, 53339-53349.	0.8	12
62	Nuclear NF-ÎºB Expression Correlates With Outcome Among Patients With Head and Neck Squamous Cell Carcinoma Treated With Primary Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 785-790.	0.4	11
63	Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer, 2020, 20, 933.	1.1	11
64	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers, 2021, 13, 1959.	1.7	11
65	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
66	Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.. Journal of Clinical Oncology, 2021, 39, 6007-6007.	0.8	10
67	A Bayesian network model of lymphatic tumor progression for personalized elective CTV definition in head and neck cancers. Physics in Medicine and Biology, 2019, 64, 165003.	1.6	9
68	A 2.5D convolutional neural network for HPV prediction in advanced oropharyngeal cancer. Computers in Biology and Medicine, 2022, 142, 105215.	3.9	9
69	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clinical and Translational Radiation Oncology, 2021, 26, 62-70.	0.9	8
70	A hidden Markov model for lymphatic tumor progression in the head and neck. Scientific Reports, 2021, 11, 12261.	1.6	8
71	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters. Strahlentherapie Und Onkologie, 2017, 193, 305-314.	1.0	7
72	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Radiotherapy and Oncology, 2018, 126, 214-221.	0.3	7

#	Article	IF	Citations
73	Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 17, 43-46.	1.2	7
74	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6
75	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Scientific Reports, 2021, 11, 4590.	1.6	6
76	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clinical and Translational Radiation Oncology, 2021, 28, 71-78.	0.9	6
77	A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer. Cancers, 2021, 13, 3413.	1.7	6
78	Patterns of care analysis for salivary gland cancer: aÂsurvey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice. Strahlentherapie Und Onkologie, 2022, 198, 123-134.	1.0	6
79	Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncology Letters, 2014, 7, 534-540.	0.8	5
80	Analysis of lymphatic metastasis and progression patterns for clinical target volume (CTV) definition in head and neck squamous cell carcinoma (HNSCC). Acta OncolÃ³gica, 2019, 58, 1519-1522.	0.8	5
81	A pattern of care analysis: Prosthetic rehabilitation of head and neck cancer patients after radiotherapy. Clinical Implant Dentistry and Related Research, 2020, 22, 333-341.	1.6	5
82	Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. Radiation Oncology, 2021, 16, 64.	1.2	5
83	Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.. Journal of Clinical Oncology, 2017, 35, 6016-6016.	0.8	5
84	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
85	Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface. Radiotherapy and Oncology, 2022, 169, 1-7.	0.3	5
86	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€“ Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
87	Second infield reâ€irradiation with a resulting cumulative equivalent dose (EQD2 max) of >180â€‰Gy for patients with recurrent head and neck cancer. Head and Neck, 2019, 41, E48-E54.	0.9	4
88	Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4411-4421.	0.8	4
89	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. Frontiers in Oncology, 2022, 12, 817692.	1.3	4
90	Stereotactic body radiotherapy of adrenal metastasesâ€”A doseâ€finding study. International Journal of Cancer, 2022, 151, 412-421.	2.3	4

#	Article	IF	Citations
91	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
92	AÂclinical example of extreme dose exposure for an implanted cardioverterâ€“defibrillator. Strahlentherapie Und Onkologie, 2017, 193, 756-760.	1.0	3
93	The Role of Regional Disease and Patterns of Treatment Failure in Primary Sinonasal Malignancies. American Journal of Rhinology and Allergy, 2022, 36, 194589242110334.	1.0	3
94	Diagnostic pathway and stage migration of sinonasal malignancies in the era of the ‹scp›COVID‹/scp›â€19 pandemic. Laryngoscope Investigative Otolaryngology, 2021, 6, 904-910.	0.6	3
95	Quantification of theÂspatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports, 2021, 11, 20890.	1.6	3
96	A dataset on patient-individual lymph node involvement in oropharyngeal squamous cell carcinoma. Data in Brief, 2022, 43, 108345.	0.5	3
97	Pediatric CNS imaging and longâ€term effects of irradiation in pediatric oncology patients. Pediatrics International, 2021, 63, 81-87.	0.2	2
98	Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2018, 36, 6019-6019.	0.8	2
99	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2018, 36, 6047-6047.	0.8	2
100	Anti-epidermal growth factor receptor immunotherapy in combination with cisplatin chemoradiation for patients with advanced head and neck carcinomaâ€”biological and clinical limitations of the triple treatment. Translational Cancer Research, 2016, 5, 199-202.	0.4	2
101	Tumor DNAâ€Methylome derived Epigenetic Fingerprint Identifies HPV â€negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. International Journal of Cancer, 2021, 150, 603.	2.3	2
102	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 2022, 14, 3031.	1.7	2
103	OC-0508: Identification of tumour sub-volumes for improved radiomic risk modelling in locally advanced HNSCC. Radiotherapy and Oncology, 2018, 127, S263-S264.	0.3	1
104	OC-0387 radiotherapy with paclitaxel/cisplatin vs. fluorouracil/cisplatin for head and neck cancer. Radiotherapy and Oncology, 2019, 133, S194.	0.3	1
105	FDG-PET/CT for oral focus assessment in head and neck cancer patients. Clinical Oral Investigations, 2022, 26, 4407-4418.	1.4	1
106	Corrigendum to â€œHPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)â€•[Radiother. Oncol. 113 (2014) 317â€“323]. Radiotherapy and Oncology, 2015, 114, 419.	0.3	0
107	Reply to: Comment on Dornoff et al.: re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlentherapie Und Onkologie, 2015, 191, 986-986.	1.0	0
108	OC-0150: Assessing the immune contexture of anal squamous cell carcinoma. Radiotherapy and Oncology, 2018, 127, S75-S76.	0.3	0

#	Article	IF	Citations
109	OC-0276: Combining different genomic signatures to improve the prognostic power for LRC after PORT-C in HNSCC. Radiotherapy and Oncology, 2018, 127, S140-S141.	0.3	0
110	OC-0324: Immune contexture in SCCHN and outcome after chemoradiotherapy in an uni- and multicentric cohort. Radiotherapy and Oncology, 2018, 127, S172-S173.	0.3	0
111	PO-1060: Leukocytosis correlates negatively with T-cell infiltration and prognosis in anal cancer. Radiotherapy and Oncology, 2018, 127, S594-S595.	0.3	0
112	OC-0390 TCGA molecular subclassification is prognostic for LRC of HNSCC after postoperative RCTx. Radiotherapy and Oncology, 2019, 133, S196.	0.3	0
113	OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC. Radiotherapy and Oncology, 2019, 133, S254-S255.	0.3	0
114	PV-0533 HPV16 viral load may explain gender differences in treatment outcome of anal squamous cell carcinoma. Radiotherapy and Oncology, 2019, 133, S281.	0.3	0
115	PV-0049 Merkel cell polyoma viral load predicts overall survival in patients with Merkel cell carcinoma. Radiotherapy and Oncology, 2019, 133, S18.	0.3	0
116	A Methylome Classifier Identifies Patients at Risk for Locoregional Recurrence after Adjuvant Radiochemotherapy in HPV-DNA negative HNSCC: a Multicenter Trial of the German Cancer Consortium- Radiation Oncology Group (DKTK-ROG). International Journal of Radiation Oncology Biology Physics, 2019, 105, S17-S18.	0.4	0
117	Induced Leukopenia In Head And Neck Cancer Patients Treated With Proton Or Photon Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, e836.	0.4	0
118	Superior Prognostic Performance of an Immunohistochemistry Trained DNA-Methylation Based PD-L1 Score in Patients with HNSCC Treated with Radiochemotherapy: A Multicenter Study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. International Journal of Radiation Oncology Biology Physics, 2020, 108, S161.	0.4	0
119	Hypoxia Methylome Classifier (HDMC) Outperforms Gene Signatures in Identifying HPV-Negative HNSCC Patients at Risk for Locoregional Failure Post Primary Radiochemotherapy: A German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Multicenter Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, e552-e553.	0.4	0
120	Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.. Journal of Clinical Oncology, 2016, 34, 6056-6056.	0.8	0
121	Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2019, 37, 6050-6050.	0.8	0